Atorvastatin

Lipitor

FDA ApprovedCardiovascular AgentsStatins
FDA: 1996Half-life: 14 hours (20-30 hours for active metabolites)Pregnancy: Category X

Overview

Atorvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular disease risk. One of the most prescribed medications worldwide.

Indications

  • Hyperlipidemia
  • Primary prevention of cardiovascular disease
  • Secondary prevention post-MI

Contraindications

  • Active liver disease
  • Unexplained persistent transaminase elevation
  • Pregnancy
  • Breastfeeding

Mechanism of Action

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL from blood.

Pharmacodynamics

Reduces LDL-C by 39-60%, increases HDL-C by 5-9%, and reduces triglycerides by 19-37% depending on dose.

Pharmacokinetics

Absorption
Rapidly absorbed. Low absolute bioavailability (14%) due to first-pass metabolism.
Distribution
Highly protein bound (≥98%).
Metabolism
Extensively metabolized by CYP3A4 to active metabolites.
Excretion
Primarily biliary/fecal.
Half-life
14 hours (20-30 hours for active metabolites)
Bioavailability
14%
Protein Binding
≥98%

Dosage

Typical dosage: 10-80 mg once daily

Available Forms

  • Tablet

Side Effects

Common

  • Myalgia
  • Arthralgia
  • Diarrhea
  • Nasopharyngitis

Serious

  • Rhabdomyolysis
  • Hepatotoxicity
  • New-onset diabetes

Rare

  • Immune-mediated necrotizing myopathy

Drug Interactions

Clarithromycinmajor

CYP3A4 inhibition increases atorvastatin levels and myopathy risk.

Grapefruit juicemoderate

Increases atorvastatin levels. Avoid large quantities.

Warnings

Pregnancy

Category X

Toxicity

Myopathy and rhabdomyolysis. Discontinue if CK significantly elevated.

Overdose

No specific antidote. Supportive care.

References

Looking for patient-friendly information? Visit RemedyDoor for easy-to-read guides about this medication.